Yeom, K.-M.; Song, Y.-G.; Yoo, J.-J.; Kim, S.G.; Kim, Y.S.
Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports. Medicina 2024, 60, 157.
https://doi.org/10.3390/medicina60010157
AMA Style
Yeom K-M, Song Y-G, Yoo J-J, Kim SG, Kim YS.
Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports. Medicina. 2024; 60(1):157.
https://doi.org/10.3390/medicina60010157
Chicago/Turabian Style
Yeom, Kyeong-Min, Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, and Young Seok Kim.
2024. "Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports" Medicina 60, no. 1: 157.
https://doi.org/10.3390/medicina60010157
APA Style
Yeom, K.-M., Song, Y.-G., Yoo, J.-J., Kim, S. G., & Kim, Y. S.
(2024). Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports. Medicina, 60(1), 157.
https://doi.org/10.3390/medicina60010157